What is NSCLC?
Non-small cell lung cancer is an umbrella term for the three most common types of lung cancer that are not small cell: adenocarcinoma (~40–45% of all lung cancers), squamous cell carcinoma (~25–30%), and large cell carcinoma (~10–15%). They are grouped together because they share similar staging, surgical approaches, and general treatment logic — as opposed to small cell lung cancer (SCLC), which behaves very differently.
The single most important step after an NSCLC diagnosis is comprehensive molecular testing (NGS). Approximately 60–70% of NSCLC adenocarcinoma patients have a targetable driver mutation — EGFR, ALK, KRAS G12C, ROS1, MET exon 14, RET, NTRK — that dramatically changes which treatment and which trials are most appropriate. Squamous cell carcinoma has fewer driver mutations but is still tested for EGFR, KRAS, and MET, and PD-L1 expression is critical for all histologies.
NSCLC Histological Subtypes
Your histology is the foundation of trial eligibility — many trials restrict enrollment to specific subtypes:
NSCLC Trial Pathways by Molecular Profile
Your molecular testing result is the primary fork in the road. Here is how it determines your trial landscape:
Driver Mutation Positive
If your NGS shows EGFR, ALK, KRAS G12C, ROS1, MET exon 14, RET fusion, or NTRK fusion: targeted therapy is first-line. Your trial search should start with the specific biomarker page. These trials almost always require confirmed molecular status and often exclude patients who haven't yet tried the approved targeted agent.
Driver Mutation Negative, PD-L1 High (≥50%)
If no driver mutation is found and PD-L1 TPS ≥50%: single-agent pembrolizumab is the standard first-line. Trials in this group test novel checkpoint inhibitor combinations — anti-TIGIT, anti-LAG-3, bispecifics — aiming to improve on pembrolizumab's ~45% response rate.
Driver Mutation Negative, PD-L1 <50%
If no driver mutation and PD-L1 is low or negative: platinum-doublet chemotherapy + pembrolizumab is the standard. Trials test novel chemo-immunotherapy backbones, antibody-drug conjugates (ADCs), and alternative immune targets for this large and heterogeneous population.
Incomplete or No Molecular Testing
If you haven't had comprehensive NGS yet: this is the most important next step before selecting a trial. Many high-value targeted therapy trials will be unavailable to you without molecular confirmation. Ask your oncologist for a comprehensive NGS panel — Foundation One, Tempus xT, Caris, or institutional panels are all acceptable.
NSCLC Trial Pathways by Stage
Stage I–II (Early-Stage)
Surgically resectable disease. Trials focus on adjuvant (post-surgery) targeted therapy — osimertinib is FDA-approved adjuvant for EGFR-mutant Stage IB–IIIA — and adjuvant immunotherapy. Neoadjuvant (pre-surgery) chemo-immunotherapy trials are a growing category. If surgery is planned or completed, ask specifically about adjuvant trial opportunities.
Stage III (Locally Advanced)
Unresectable Stage III NSCLC is treated with concurrent chemoradiation followed by durvalumab (Imfinzi) maintenance — the PACIFIC regimen. Trials in this space test alternatives to durvalumab, novel immunotherapy maintenance agents, and combinations with targeted therapy for driver-mutation-positive Stage III patients.
Stage IV (Metastatic)
The largest trial population. Treatment is guided by molecular profile and PD-L1 as described above. Trial options are most extensive here — first-line trials, second-line trials after progression, resistance mechanism-specific trials, and basket trials open to any solid tumor with a specific biomarker.
Recurrent After Prior Treatment
After progression on first-line therapy, trial eligibility narrows based on prior treatment history. Trials in this space often require specific prior therapy as an inclusion criterion (e.g., "must have progressed on platinum chemotherapy"). Knowing exactly what you received and when is essential for identifying eligibility.
NSCLC FAQs
Before looking at any clinical trials, make sure you have: (1) Comprehensive NGS panel testing for at minimum EGFR, ALK, KRAS G12C, ROS1, MET exon 14, RET, NTRK, BRAF V600E, and HER2. If your oncologist only ordered single-gene tests, ask for a broader panel — targeted therapy trials require confirmed molecular status. (2) PD-L1 IHC with TPS score. (3) Histology confirmation — adenocarcinoma vs. squamous vs. other. If your initial biopsy was small or the specimen was limited, a repeat biopsy may be worth discussing. Many high-value trials are only accessible once you have complete molecular data.
First, confirm the testing was truly comprehensive — some smaller panels miss MET exon 14 skipping, NTRK fusions, or RET fusions. If the panel was comprehensive and no driver is found, your trial options are primarily immunotherapy-based. With PD-L1 ≥50%, look for trials building on or comparing to single-agent pembrolizumab. With lower PD-L1, look for chemo-immunotherapy combination trials, and increasingly for trials targeting alternative immune checkpoints like TIGIT and LAG-3 that don't depend on PD-L1 as a biomarker. Squamous cell patients without drivers should specifically look at trials in squamous NSCLC, where FGFR inhibition and novel immunotherapy combinations are being studied.
Yes, significantly. Small cell lung cancer (SCLC) and NSCLC are biologically distinct diseases with almost entirely separate trial landscapes. SCLC grows faster, spreads earlier, is more sensitive to initial chemotherapy (carboplatin + etoposide), but relapses quickly and has fewer targetable molecular alterations. NSCLC has a much wider range of molecular drivers and targeted therapy options. Nearly all clinical trials specify NSCLC or SCLC explicitly in their eligibility criteria — the two are almost never interchangeable in trial enrollment. If there is any ambiguity in your diagnosis (e.g., mixed histology, or LCNEC), clarifying this with your oncologist before applying to trials is essential.
There are somewhat fewer molecularly targeted trials, but not fewer trials overall. Squamous cell NSCLC has fewer druggable driver mutations than adenocarcinoma — EGFR and ALK are rare in squamous histology. However, the immunotherapy trial landscape is essentially equivalent: pembrolizumab, nivolumab, atezolizumab, and combination regimens are all approved and trialed in squamous NSCLC. Squamous-specific targets being actively studied include FGFR1 amplification, KEAP1/NFE2L2 pathway alterations, and EGFR exon 20 insertions. Some trials specifically enrich for squamous histology or run squamous-specific cohorts within larger basket trials.
(1) Pathology report confirming NSCLC histology (adenocarcinoma, squamous, or NOS) and ideally IHC markers (TTF-1, p40/p63). (2) Comprehensive NGS report — the actual report, not just a summary letter, as trial coordinators often need to verify specific mutations and testing methodology. (3) PD-L1 IHC result with TPS percentage and antibody clone used (22C3 for most pembrolizumab trials). (4) Recent CT scan of chest and abdomen (within 4–6 weeks for most trials), plus brain MRI if CNS metastases are present or suspected. (5) Full treatment history — every prior drug, start/end dates, best response, and reason for stopping. (6) ECOG performance status documented by your oncologist. Most trials require ECOG 0–1; some accept ECOG 2.
Ready to find your matching NSCLC trials?
Upload your pathology report, NGS results, or imaging. We'll identify your histology and molecular profile, match you to recruiting trials, and give you an eligibility breakdown for each one.